Nevertheless, when we measured foci of infection across 72h, we found that RSV L305I resulted in significantly fewer foci than RSV WT (Fig.2eand Supplementary Fig.2). study suggests that Captopril select amino acids in RSV-F may act as conformational switches for RSV Rabbit Polyclonal to SLC25A12 to evade host serum antibodies. This work has important implications in understanding RSV evolution and resistance as it suggests that mutational resistance to neutralizing antibodies can occur at sites distal to antigenic epitopes, significantly altering antibody sensitivity to viral infection. These unique antigenic landscape changes should be considered in the context of vaccine and therapeutic development in order to better understand viral mechanisms of evasion and resistance. Subject terms:Biochemistry, Computational biology and bioinformatics, Immunology, Microbiology, Medical research, Pathogenesis == Introduction == Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalization and the second leading cause of infant mortality worldwide1. There are an estimated 33 million cases of RSV-associated acute-lower respiratory tract infections annually, over 100,000 of which lead to death1. Immunocompromised and elderly populations are increasingly being recognized as vulnerable high-risk groups for severe disease2. Despite the enormous disease burden presented by RSV, there are few effective antiviral therapies readily available for the treatment of active infection. Biologics in the form of prophylactic monoclonal antibodies provide a means of passive immunization and are the treatment of choice for RSV infection. Until recently, the prophylactic monoclonal antibody Palivizumab (PZMB) was the only preventative therapeutic available for high-risk infants. PZMB is administered monthly throughout the RSV season to only the highest-risk infants. PZMB is costly, has variable efficacy, and leaves a large population of infants and susceptible adults unprotected3. In 2023, the FDA approved Nirsevimab for use in Captopril all infants under 8 months old entering their first RSV season, and Merck has a Phase III biologic – Clesrovimab – in development4. In contrast to PZMB, Nirsevimab and Clesrovimab are more potent, and thus administration is only required once per RSV season. Two new adult vaccines created by Pfizer (Abrysvo) and GSK (Arexvy) were also approved for use in the elderly, and pregnant women respectively5,6. In light of these promising advancements, it is critical that we better understand how RSV might adapt to evade the selective pressures that are sure to be elicited by novel therapeutics. RSV is under consistent evolutionary pressure while circulating in the human population. While the primary burden of RSV is in infants, it Captopril continuously circulates in healthy adults and accounts for approximately 1535% of all respiratory virus cases in any given season7. The antiviral immune response mounted during the course of RSV infection places selective pressures on the virus that lead to quasi-species displaying an array of polymorphisms. Like other RNA viruses, RSV adapts readily while circulating in the population, particularly in the highly variable gene that encodes the attachment glycoprotein, RSV-G8. Genetically distinct viruses impact viral load and pathology in humans during Captopril subsequent RSV seasons, which we have previously correlated with viral replication in tissue culture9. There are two subtypes of RSV, subtype A (RSV-A) and subtype B (RSV-B). RSV-A and RSV-B are estimated to have diverged from their most recent common ancestor approximately 338 years ago10. In any given season, Captopril one subtype typically predominates over the other and alternates annually11. However, some reports show that the two subtypes can co-circulate in the population and even present as co-infections in the same patient12. Overall, RSV-A and RSV-B share about 90% nucleotide sequence identity, with the highest regions of sequence variability occurring in the RSV-M2-2 and RSV-G genes13. RSV-A and RSV-B are primarily differentiated by high amino acid variability between their RSV-G glycoproteins14. Notably, there are also select residues in other viral proteins, including RSV-F,.